Printer Friendly

Othera Pharmaceuticals Announces Results from First Human Phase I Trial For OT-551.

EXTON, Pa. -- Othera Pharmaceuticals, Inc.
Topical Eye Drop Antioxidant Therapy Targets Oxidative Damage
 Leading to the Most Common Form of Cataracts

 Study meets all safety and comfort endpoints and positions Othera
 to move forward with planned Phase II study later in 2005

Othera Pharmaceuticals, Inc. today announced that its Phase I Safety and Comfort Study of OT-551, a topical eye drop pharmaceutical, met its primary endpoints. Othera Pharmaceuticals is a privately-held ophthalmic pharmaceutical company developing proprietary drugs to treat or prevent the leading causes of blindness. Following on these positive Phase I results, Othera plans to initiate a Phase II clinical trial to study OT-551's ability to slow or halt the development of a type of nuclear cataract, which is considered to be the most common form of age-related cataract. That study, set to begin in the second half of 2005, will involve 100 patients who will receive treatment over a 12 month period.

"The positive results from the Phase I trial represent a significant milestone for Othera, positioning us to move forward with our planned Phase II study for cataracts and to pursue other ophthalmic indications for OT-551. Chief among these other potential applications is the treatment of age-related macular degeneration," said David S. Joseph, chairman and CEO of Othera.

Othera intends to file a supplement to its OT-551 Investigational New Drug (IND) application with the FDA for use of OT-551 as a treatment for age-related macular degeneration (AMD) in 2006. Separately, the company plans to file another IND in 2006 for OT-730, a second eye drop product, currently in preclinical development as a treatment for glaucoma.

Othera will present at the BIO2005 meeting, to be held in Philadelphia from June 19-22.

About the Company

Othera Pharmaceuticals, Inc. ( is a privately-held, ophthalmic pharmaceutical company located in Exton, Pennsylvania. Othera is developing proprietary drugs to treat or prevent the three leading causes of blindness and vision impairment in the world - cataracts, age-related macular degeneration (AMD) and glaucoma. The Company's lead drug, OT-551, is a potent antioxidant topical eye drop to prevent the development of cataracts and AMD. With age, ocular levels of natural antioxidants, such as vitamins and enzymes, tend to decrease over time, leaving the eye susceptible to oxidative damage and disease. OT-551 mimics some of these natural compounds, but owing to its chemistry and catalytic nature, has demonstrated high antioxidant activity at low levels in preclinical studies of both cataract and AMD disease models. Othera's second drug, OT-730, is a novel beta blocker-like eye drop treatment for glaucoma that is designed to provide the same efficacy as current glaucoma therapies, but without the systemic side effects normally associated with this drug class.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:May 25, 2005
Previous Article:Bentley Announces BE Careers Network.
Next Article:Changes in Endesa's Board of Directors.

Related Articles
Research provides golden opportunity for physicians: An overview of clinical trials and how to conduct them. (Clinical Trials).
Othera Pharmaceuticals Closes $13 Million in Venture Capital Financing.
Othera Pharmaceuticals Completes $16 Million Venture Capital Financing.
The hepatitis C drug development pipeline.
An overview of the drug development process.
Othera Pharmaceuticals Elects Hans Mueller to Board.
Othera Pharmaceuticals Initiates Phase 2 Clinical Trial for OT-551 in Cataract Prevention; Trial to Address Rapidly-Progressing Form of Cataracts...
Othera Pharmaceuticals and the National Eye Institute Collaborate in Dry AMD Study; A Phase II Study of OT-551 Antioxidant Eye Drop in Participants...
Othera Pharmaceuticals and the National Eye Institute Commence Dry AMD Study.
Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters